The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation
Table 1
Clinical characteristics of patients of the two groups.
Parameters
Sitagliptin group (n = 137)
Conventional group (n = 137)
P value
Age (years)
63.8 ± 9.7
63.6 ± 1.0
0.90
Gender (males) (%)
83 (61)
82 (60)
1.00
Body mass index
25.0 ± 4.3
25.0 ± 3.8
0.88
Current smoking
30 (22)
29 (21)
0.22
Duration of diabetes (years)
17.2 ± 8.5
17.3 ± 8.7
0.94
HbA1c at baseline (mmol/mol)
64.9 ± 11.9
63.9 ± 10.6
0.45
Systolic blood pressure (mmHg)
130 ± 16
132 ± 14
0.88
Total cholesterol at baseline (mmol/l)
5.02 ± 0.91
4.94 ± 0.86
0.50
HDL cholesterol at baseline (mmol/l)
1.46 ± 0.37
1.39 ± 0.38
0.14
Triglyceride at baseline (mmol/l)
1.13 (0.83, 1.55)
1.17 (0.90, 1.72)
0.22
eGFR (ml/min/1.73 m2)
77.7 ± 21.2
79.7 ± 24.2
0.47
Mean IMT (mm)
0.84 ± 0.19
0.84 ± 0.21
0.81
Right maximum IMT (mm)
1.04 ± 0.29
1.06 ± 0.40
0.69
Left maximum IMT (mm)
1.10 ± 0.32
1.11 ± 0.41
0.87
Use of oral glucose-lowering agents
Metformin
49 (36)
48 (35)
1.00
Sulfonylurea
17 (12)
15 (11)
0.85
Glinides
2 (1)
19 (14)
<0.001
Thiazolidinediones
13 (9)
11 (8)
0.83
α-Glucosidase inhibitor
41 (30)
42 (31)
1.00
Others
Angiotensin-converting enzyme inhibitors
8 (6)
4 (3)
0.59
Angiotensin II receptor blockers
53 (39)
69 (50)
0.07
Statins
66 (48)
63 (46)
0.81
Antiplatelet agents
29 (21)
30 (22)
1.00
Data are number (%) of patients or mean ± SD values. IMT, intima-media thickness; eGFR, glomerular filtration rate.